Share this
Bavarian Nordic Acquires Two Commercial Vaccines from GlaxoSmithKline for €796 Million
Silence Therapeutics Enters Collaboration With Mallinckrodt Worth up to $2 Billion
Jazz Pharmaceuticals Acquisition of Redx Pharma's pan-RAF Inhibitor Program Valued up to $206 Million
Mission Therapeutics Enters Collaboration Agreement with AbbVie
Cooley Advises F-star on Collaborative Agreement with Denali Therapeutics
Cooley Advises on the Admission to AIM of SalvaRx Group plc
Immunocore Limited Series A $320 Million Financing
Cooley Advises Immunocore on Largest European Private Life Sciences Financing on Record
Bavarian Nordic Option and Licence Agreement With Bristol-Myers Squibb
Bavarian Nordic MVA-BN Ebola Vaccine Licence to Janssen
CRT Pioneer Fund Licence Agreements
Meda: Rottapharm l Madaus Acquisition
ALK-Abello Partnership Agreement with Abbott